Thermo Fisher announces collaboration with Northeastern University


Researchers at BATL will be in a position to develop workflows for biotherapeutics analysis and share methods across the industry to drive advancements

Thermo Fisher Scientific and the Biopharmaceutical Analysis Training Laboratory (BATL) at Northeastern University have entered into a collaborative agreement in a bid to advance analytical capabilities and drive innovation across the biopharmaceutical industry in areas including personalised medicine, monoclonal antibodies and gene and cell therapies.

BATL’s technical training programs for regulators, industry personnel and academics, complemented by Thermo Fisher’s liquid chromatography-mass spectrometry technology, will facilitate analytical solutions and training designed to meet the current needs of the industry. The implementation of the Thermo Scientific Orbitrap Exploris 240 mass spectrometer and Thermo Scientific Vanquish Duo UHPLC System within BATL’s training facility will enable the analysis of the complex molecules defining the medicines of the future, the companies say.

Using the power of these analytical systems,. Sign up for your free email newsletter

BATL, which typically works across an extensive range of samples of varying characteristics, chose the Orbitrap Exploris 240 due to the system’s ability to deliver consistent results regardless of sample complexity, the company says. It additionally selected the Vanquish Duo UHPLC System for its ability to be operated in tandem mode, eliminating wait time for column equilibration. “In the last few decades we’ve seen the development of novel biotherapies, such as gene therapies and personalized medicines, to treat a myriad of diseases, and this level of innovation within the biopharmaceutical industry continues to grow,” said Eric Grumbach, Director, biopharma/pharma, chromatography and mass spectrometry, Thermo Fisher Scientific. “With new therapies, there comes a need for forward-looking analytical techniques and methods to deliver the sensitivity and accuracy required to ensure the safety and efficacy of drugs. Our collaboration with BATL will provide biopharmaceutical organizations with the analytical solutions required to answer groundbreaking scientific questions, while still meeting regulations and optimizing their operations.” Jared Auclair, associate dean of professional programs and graduate affairs and director of the Biopharmaceutical Analysis Training Laboratory said, “Our progressive training programs focus on the science- and risk-based evaluation of therapeutics, allowing scientists to reduce the regulatory burden and deliver potentially lifesaving drugs to patients more quickly. This collaboration with Thermo Fisher not only provides us with the analytical power we need from our instruments, but also allows us to drive the development of valuable biopharmaceutical characterization and monitoring workflows to address the ever- evolving analysis needs within the industry.”

Features Companies